[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

FI906367A0 - Terapeutiska nukleosider. - Google Patents

Terapeutiska nukleosider.

Info

Publication number
FI906367A0
FI906367A0 FI906367A FI906367A FI906367A0 FI 906367 A0 FI906367 A0 FI 906367A0 FI 906367 A FI906367 A FI 906367A FI 906367 A FI906367 A FI 906367A FI 906367 A0 FI906367 A0 FI 906367A0
Authority
FI
Finland
Prior art keywords
nucleosider
therapeutic
therapeutic nucleosider
Prior art date
Application number
FI906367A
Other languages
English (en)
Other versions
FI106461B (fi
FI906367A (fi
Inventor
Susan Mary Daluge
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/455,201 external-priority patent/US5034394A/en
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of FI906367A0 publication Critical patent/FI906367A0/fi
Publication of FI906367A publication Critical patent/FI906367A/fi
Priority to FI970666A priority Critical patent/FI105813B/fi
Application granted granted Critical
Publication of FI106461B publication Critical patent/FI106461B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/42—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups or hydroxy groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50—Three nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/10—Systems containing only non-condensed rings with a five-membered ring the ring being unsaturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FI906367A 1989-12-22 1990-12-21 Menetelmä terapeuttisesti käyttökelpoisten enantiomeeristen yhdisteiden valmistamiseksi sekä menetelmässä käyttökelpoinen välituote FI106461B (fi)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FI970666A FI105813B (fi) 1989-12-22 1997-02-17 Enantiomeerisia välituotteita

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/455,201 US5034394A (en) 1988-06-27 1989-12-22 Therapeutic nucleosides
US45520189 1989-12-22

Publications (3)

Publication Number Publication Date
FI906367A0 true FI906367A0 (fi) 1990-12-21
FI906367A FI906367A (fi) 1991-06-23
FI106461B FI106461B (fi) 2001-02-15

Family

ID=23807819

Family Applications (2)

Application Number Title Priority Date Filing Date
FI906367A FI106461B (fi) 1989-12-22 1990-12-21 Menetelmä terapeuttisesti käyttökelpoisten enantiomeeristen yhdisteiden valmistamiseksi sekä menetelmässä käyttökelpoinen välituote
FI20001175A FI20001175A (fi) 1989-12-22 2000-05-16 Enantiomeerisia yhdisteitä, jotka ovat oleellisesti vapaita vastaenantiomeereista

Family Applications After (1)

Application Number Title Priority Date Filing Date
FI20001175A FI20001175A (fi) 1989-12-22 2000-05-16 Enantiomeerisia yhdisteitä, jotka ovat oleellisesti vapaita vastaenantiomeereista

Country Status (30)

Country Link
EP (3) EP0921114A1 (fi)
JP (2) JPH11158160A (fi)
CN (1) CN1028106C (fi)
AP (1) AP196A (fi)
AT (1) ATE181917T1 (fi)
AU (1) AU633672B2 (fi)
CA (1) CA2033044C (fi)
CY (1) CY2145B1 (fi)
CZ (1) CZ283481B6 (fi)
DE (2) DE69033197T2 (fi)
DK (1) DK0434450T3 (fi)
ES (1) ES2133138T3 (fi)
FI (2) FI106461B (fi)
GR (1) GR3031100T3 (fi)
HK (1) HK1009600A1 (fi)
HU (3) HU220067B (fi)
IE (3) IE990826A1 (fi)
IL (1) IL96748A (fi)
LU (1) LU90426I2 (fi)
MX (1) MX9203215A (fi)
MY (1) MY104575A (fi)
NL (1) NL990028I2 (fi)
NZ (1) NZ236593A (fi)
PL (1) PL167097B1 (fi)
PT (1) PT96321B (fi)
RU (2) RU2068849C1 (fi)
SG (1) SG49685A1 (fi)
SK (2) SK658390A3 (fi)
TW (2) TW473466B (fi)
ZA (1) ZA9010365B (fi)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT89482B (pt) * 1988-01-20 1994-02-28 Univ Minnesota Processo para a preparacao de derivados de nucleosidos disesoxi-didesidro-carboxilico
CA2001401A1 (en) * 1988-10-25 1990-04-25 Claude Piantadosi Quaternary amine containing ether or ester lipid derivatives and therapeutic compositions
GB9108376D0 (en) * 1991-04-19 1991-06-05 Enzymatix Ltd Cyclopentenes
GB9204015D0 (en) * 1992-02-25 1992-04-08 Wellcome Found Therapeutic nucleosides
GB9205071D0 (en) * 1992-03-09 1992-04-22 Wellcome Found Therapeutic nucleosides
CA2164717C (en) * 1993-06-10 2009-10-20 Louis S. Kucera Method of combatting hepatitis b virus infection
GB9402161D0 (en) 1994-02-04 1994-03-30 Wellcome Found Chloropyrimidine intermediates
GB9417249D0 (en) * 1994-08-26 1994-10-19 Wellcome Found A novel salt
WO1996006620A2 (en) * 1994-08-29 1996-03-07 Wake Forest University Lipid analogs for treating viral infections
US7135584B2 (en) 1995-08-07 2006-11-14 Wake Forest University Lipid analogs for treating viral infections
US5977061A (en) * 1995-04-21 1999-11-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic N6 - substituted nucleotide analagues and their use
GB9600142D0 (en) * 1996-01-05 1996-03-06 Wellcome Found Chemical compounds
AP9801419A0 (en) * 1996-06-25 1998-12-31 Glaxo Group Ltd Combination comprising VX478, zidovudine, FTC and or 3
ID18739A (id) 1996-06-25 1998-05-07 Glaxo Group Ltd Kombinasi-kombinasi antiviral
SK284810B6 (sk) * 1997-05-13 2005-12-01 Lonza Ag Spôsob výroby (1S,4R)- alebo (1R,4S)-4-(2-amino-6-chlór-9-H- purín-9-yl)-2-cyklopentén-1-metanolu
AU769660B2 (en) * 1997-05-17 2004-01-29 Glaxo Group Limited Carbocyclic nucleoside hemisulfate and its use in treating viral infections
GB9709945D0 (en) * 1997-05-17 1997-07-09 Glaxo Group Ltd A novel salt
GB9721780D0 (en) * 1997-10-14 1997-12-10 Glaxo Group Ltd Process for the synthesis of chloropurine intermediates
AU2702899A (en) * 1997-10-24 1999-05-17 Glaxo Group Limited Process for preparing a chiral nucleoside analogue
EP1032573A1 (en) * 1997-11-12 2000-09-06 Glaxo Group Limited Process for preparing a chiral nucleoside analogue
SK284595B6 (sk) * 1997-11-27 2005-07-01 Lonza Ag Spôsob výroby (1S,4R)-4-(2-amino-6-chlór-9H-purín-9-yl)-2- cyklopentén-1-metanolu alebo jeho solí
YU44900A (sh) 1998-01-31 2003-01-31 Glaxo Group Limited Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola
GB9802472D0 (en) * 1998-02-06 1998-04-01 Glaxo Group Ltd Pharmaceutical compositions
GB9820417D0 (en) * 1998-09-18 1998-11-11 Glaxo Group Ltd Antiviral combinations
GB9821058D0 (en) 1998-09-28 1998-11-18 Univ Cardiff Chemical compound
SK285271B6 (sk) * 1998-10-30 2006-10-05 Lonza Ag Spôsob výroby 4-[(2',5'-diamino-6'-halogénpyrimidin-4'- yl)amino]cyklopent-2-enylmetanolov
US6433170B1 (en) 1998-10-30 2002-08-13 Lonza Group Method for producing 4-[2',5'-diamino-6'-halopyrimidine-4'-yl)amino]- cyclopent-2-enylmethanols
GB9903091D0 (en) * 1999-02-12 1999-03-31 Glaxo Group Ltd Therapeutic nucleoside compound
US7026469B2 (en) 2000-10-19 2006-04-11 Wake Forest University School Of Medicine Compositions and methods of double-targeting virus infections and cancer cells
JP2003516408A (ja) * 1999-12-10 2003-05-13 グラクソ グループ リミテッド 抗ウィルス薬としての（１Ｒ，シス）−４−［４−アミノ−７Ｈ−ピロロ（２，３−ｄ）ピリミジン−７−イル］−２−シクロペンテン−１−メタノール類縁物
PE20010915A1 (es) * 1999-12-10 2001-09-29 Glaxo Group Ltd Analogos de (1s, cis)-4-(2-amino-9h-purin-9-il)-2-ciclopenten-1-metanol para uso en el tratamiento de infecciones virales
DE10042655A1 (de) 2000-08-31 2002-03-14 Aventis Pharma Gmbh Verfahren zur Herstellung von Inhibitoren der Zell-Adhäsion
US7309696B2 (en) 2000-10-19 2007-12-18 Wake Forest University Compositions and methods for targeting cancer cells
EA006020B1 (ru) 2001-06-29 2005-08-25 Инститьют Оф Оргэник Кемистри Энд Байокемистри Оф Зе Экэдеми Оф Сайэнс Оф Зе Чек Рипаблик Производные 6-[2-(фосфонометокси)алкокси]пиримидинов, обладающие антивирусной активностью, способ их получения (варианты) и способ лечения вирусной инфекции
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
US7550261B2 (en) 2001-08-21 2009-06-23 Smithkline Beecham Corporation Method of screening for drug hypersensitivity reaction
WO2003018745A2 (en) * 2001-08-21 2003-03-06 Glaxo Group Limited Method of screening for drug hypersensitivity reaction
KR100871648B1 (ko) 2001-08-31 2008-12-03 톰슨 라이센싱 조건부 액세스 시스템을 구현하는 방법, 컨텐트를 전송하는 방법 및 그 장치 및 컨텐트를 수신하고 처리하는 방법 및 그 장치
US6780635B2 (en) 2001-12-27 2004-08-24 Council Of Scientific And Industrial Research Process for the preparation of optically active azabicyclo heptanone derivatives
CN1302779C (zh) * 2002-06-27 2007-03-07 美迪维尔公司 含有阿巴卡韦和阿洛夫定的药物制剂及其用途
KR101102815B1 (ko) 2003-06-16 2012-01-05 케이.유.루벤 리서치 앤드 디벨럽먼트 항바이러스 뉴클레오티드 유사체인 포스포네이트기를 갖는 피리미딘 화합물
GB0320738D0 (en) 2003-09-04 2003-10-08 Glaxo Group Ltd Novel process
EP1857458A1 (en) * 2006-05-05 2007-11-21 SOLMAG S.p.A. Process for the preparation of abacavir
JP5334852B2 (ja) * 2006-09-28 2013-11-06 エステヴェ キミカ， エス．エー． アバカビルの製造方法
EP1905772A1 (en) 2006-09-28 2008-04-02 Esteve Quimica, S.A. Process for the preparation of abacavir
EP1939196A1 (en) * 2006-12-21 2008-07-02 Esteve Quimica, S.A. Process for the preparation of abacavir
PT2159224E (pt) 2007-06-18 2012-10-24 Sunshine Lake Pharma Co Ltd Tiazolil dihidropirimidinas substituídas com bromo-fenilo
EP2085397A1 (en) 2008-01-21 2009-08-05 Esteve Quimica, S.A. Crystalline form of abacavir
TWI444384B (zh) 2008-02-20 2014-07-11 Gilead Sciences Inc 核苷酸類似物及其在治療惡性腫瘤上的用途
JP5656837B2 (ja) * 2008-09-09 2015-01-21 アストラゼネカ アクチボラグ ［１Ｓ−［１α，２α，３β（１Ｓ＊，２Ｒ＊），５β］］−３−［７−［２−（３，４−ジフルオロフェニル）−シクロプロピルアミノ］−５−（プロピルチオ）−３Ｈ−１，２，３−トリアゾロ［４，５−ｄ］ピリミジン−３−イル］−５−（２−ヒドロキシエトキシ）シクロペンタン−１，２−ジオールおよびその中間体の製造方法
TWI481611B (zh) * 2012-01-03 2015-04-21 Cellceutix Corp 碳環核苷及其醫藥用途及組合物
US9457028B2 (en) 2013-02-27 2016-10-04 Kyoto University Pharmaceutical composition for use in prevention or treatment of cancer
EP3052499B1 (en) 2013-10-03 2017-11-15 Lupin Limited Crystalline abacavir hydrochloride monohydrate and process for its preparation
CN104558035B (zh) * 2013-10-22 2017-12-19 连云港恒运药业有限公司 一种替诺福韦前药的纯化方法
CN104788451A (zh) * 2014-01-21 2015-07-22 浙江九洲药业股份有限公司 一种阿巴卡韦的制备方法
CN109239253B (zh) * 2018-09-21 2021-07-09 江苏威奇达药业有限公司 一种阿巴卡韦的杂质的高效液相检测方法
WO2021209563A1 (en) 2020-04-16 2021-10-21 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL84842A0 (en) * 1986-12-24 1988-06-30 Lilly Co Eli Immunoglobulin conjugates
PT89482B (pt) * 1988-01-20 1994-02-28 Univ Minnesota Processo para a preparacao de derivados de nucleosidos disesoxi-didesidro-carboxilico
GB8815265D0 (en) * 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
JPH02164881A (ja) * 1988-10-24 1990-06-25 Wellcome Found Ltd:The 治療用ヌクレオシド化合物
NZ233197A (en) * 1989-04-13 1991-11-26 Richard Thomas Walker Aromatically substituted nucleotide derivatives, intermediates therefor and pharmaceutical compositions
US4939252A (en) * 1989-04-20 1990-07-03 Hoffmann-La Roche Inc. Novel intermediates for the preparation of Carbovir

Also Published As

Publication number Publication date
NL990028I1 (nl) 1999-11-01
PT96321B (pt) 1998-06-30
ATE181917T1 (de) 1999-07-15
SK280216B6 (sk) 1999-10-08
NZ236593A (en) 1994-01-26
TW473466B (en) 2002-01-21
LU90426I2 (fr) 1999-10-06
IL96748A (en) 1995-07-31
HU9008407D0 (en) 1991-07-29
AP196A (en) 1992-06-30
IL96748A0 (en) 1991-09-16
MX9203215A (es) 1992-07-01
SK247092A3 (en) 1999-06-11
PT96321A (pt) 1991-09-30
DE69033197T2 (de) 1999-10-28
PL167097B1 (pl) 1995-07-31
DK0434450T3 (da) 2000-01-31
IE990826A1 (en) 2000-12-13
HK1009600A1 (en) 1999-06-04
FI106461B (fi) 2001-02-15
DE19975058I1 (de) 2007-01-25
AU633672B2 (en) 1993-02-04
GR3031100T3 (en) 1999-12-31
CN1028106C (zh) 1995-04-05
FI906367A (fi) 1991-06-23
SK658390A3 (en) 1999-10-08
HU220630B1 (hu) 2002-03-28
SK280000B6 (sk) 1999-06-11
HU9902539D0 (en) 1999-10-28
EP0434450B1 (en) 1999-07-07
EP0921121A1 (en) 1999-06-09
HU220067B (hu) 2001-10-28
HU219454B (hu) 2001-04-28
DE69033197D1 (de) 1999-08-12
IE990825A1 (en) 2000-12-13
CA2033044A1 (en) 1991-06-23
RU2091386C1 (ru) 1997-09-27
CN1054981A (zh) 1991-10-02
RU2068849C1 (ru) 1996-11-10
MY104575A (en) 1994-04-30
EP0434450A3 (en) 1992-07-08
TW371660B (en) 1999-10-11
CZ658390A3 (en) 1997-11-12
AP9000234A0 (en) 1991-01-31
JPH11158160A (ja) 1999-06-15
EP0434450A2 (en) 1991-06-26
CY2145B1 (en) 2002-06-21
CZ283481B6 (cs) 1998-04-15
NL990028I2 (nl) 2000-02-01
FI20001175A (fi) 2000-05-16
EP0921114A1 (en) 1999-06-09
HU9902543D0 (en) 1999-10-28
PL288403A1 (en) 1992-06-26
SG49685A1 (en) 1998-06-15
CA2033044C (en) 1999-07-13
AU6841990A (en) 1991-06-27
ZA9010365B (en) 1992-08-26
IE904652A1 (en) 1991-07-17
JPH11343292A (ja) 1999-12-14
ES2133138T3 (es) 1999-09-01

Similar Documents

Publication Publication Date Title
FI906367A (fi) Terapeutiska nukleosider.
FI913899A0 (fi) Terapeutiska aerosolblandningar.
ATE120194T1 (de) Therapeutische nuleoside.
FI903656A0 (fi) Terapeutiska kinuklidinfoereningar.
FI883757A (fi) Terapeutiska nukleosider.
FI881651A0 (fi) Terapeutiska nukleosider.
FI914805A0 (fi) Ickegrafitiska taendningsresistanta strukturer.
FI904854A0 (fi) Terapeutiska nukleosider.
FI902973A0 (fi) Magnetfaeltsgenerator foer terapeutiska aendamaol.
FI905632A0 (fi) Imidazolfungicider.
FI893897A (fi) Terapeutiska nukleosider.
FI890465A (fi) Bandformig foerpackningsmaterial.
FI923486A0 (fi) Terapeutiska aemnen.
FI881216A (fi) Terapeutiska nukleosider.
FI894321A0 (fi) Terapeutiska aemnen.
FI890191A0 (fi) Frekvensmodulerad saendarmottagare.
FI890327A0 (fi) Sidobalkfaeste foer bilkorgsutraetningsanordning.
FI910753A (fi) Terapeutiska nukleocider.
FI923528A0 (fi) Terapeutiska aemnen.
FI912852A0 (fi) Terapeutiska dekapeptider.
FI890359A0 (fi) Slitagetestanordning.
NO901573L (no) Terapeutiske midler.
NO901574L (no) Terapeutiske midler.
ES1011518Y (es) Amnioscopio.
FI892374A0 (fi) Anordning foer foerflyttning av patient.

Legal Events

Date Code Title Description
FG Patent granted

Owner name: THE WELLCOME FOUNDATION LIMITED

SPCG Supplementary protection certificate granted

Spc suppl protection certif: L190

Extension date: 20140627